In September, the FDA cleared for marketing the first laboratory assay for assessing a critically ill patient’s risk of developing moderate to severe acute kidney injury (AKI). This new test comes to market at a time when clinical trial data is providing a clearer picture of the relationship between AKI and both short-term (death, prolonged hospitalization) and long-term risk for cardiovascular events and chronic kidney disease (CKD). Indeed AKI is a major risk factor for progression toward and worsening of CKD.
This program is designed for laboratorians, kidney specialists, pathologists, laboratory directors, clinicians, diagnostic manufacturers, and other medical professionals involved in the diagnosis or management of patients with acute kidney injury or kidney disease.
John A. Kellum, MD, MCCM, Professor of Critical Care Medicine, Medicine, Bioengineering, and Clinical and Translational Science, Vice Chair for Research in the Department of Critical Care Medicine, and Director of the Center for Critical Care Nephrology for the Clinical Research Investigation and Systems Modeling of Acute illness (CRISMA) Center at the University of Pittsburgh, Pittsburgh, PA
Dr. Kellum is the principal investigator and co-investigator on several NIH-funded studies in clinical and basic science research including grants from NHLBI, NIGMS, NIDDK and HRSA. His research interests span various aspects of Critical Care Medicine, but center in critical care nephrology (including acid-base, acute kidney injury and renal replacement therapy), sepsis and multi-organ failure, brain death and organ donor management and translational research. He has authored more than 300 publications and has won several awards for teaching. He lectures widely and has given more than 400 seminars and invited lectures related to his research.